Stock Events

Stock Events

Atossa Therapeutics 

$2.57
327
-$0.22-7.89% 15:13 Today

Statistics

Day High
2.78
Day Low
2.57
52W High
17.7
52W Low
1.75
Volume
35,200
Avg. Volume
156,625
Mkt Cap
25.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.11
-0.75
-0.4
-0.04
Expected EPS
-0.895
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-34.77MNet Income

Analyst Ratings

20.33Average Price Target
The highest estimate is 25.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ATOS. It's not an investment recommendation.
Amazon
43
AMZN
Apple
41
AAPL
NVIDIA
41
NVDA
Microsoft
39
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap152.69B
Pfizer is involved in developing treatments in various therapeutic areas, including those Atossa is targeting, making them direct competitors in the pharmaceutical space.
Merck
MRK
Mkt Cap335.14B
Merck operates in similar therapeutic areas as Atossa, including breast cancer treatments, positioning them as competitors.
Novartis
NVS
Mkt Cap286.78B
Novartis competes with Atossa in the oncology sector, particularly in developing treatments for breast cancer.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences focuses on innovative therapies, including for cancer, directly competing with Atossa's therapeutic development efforts.
AMGEN
AMGN
Mkt Cap224.63B
Amgen's focus on biologics and treatments for serious illnesses places them in competition with Atossa, especially in cancer therapy.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie's work in oncology and focus on innovative treatments make them a competitor to Atossa in the pharmaceutical and biotech industry.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca's extensive research in oncology, including breast cancer, positions them as a competitor to Atossa.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb's involvement in cancer research and development of oncology treatments competes with Atossa's focus areas.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly's commitment to cancer research, including breast cancer, makes them a direct competitor to Atossa in the pharmaceutical industry.

About

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Show more...
CEO
Steven C. Quay
Employees
14
Country
United States
ISIN
US04962H7044
WKN
000A41ZVB

Listings

MU
DE
YAG2.MU
STU
DE
YAG.STU
MX
MX
ATOS.MX
MU
DE
YAG.MU

0 Comments

Share your thoughts

FAQ

What is Atossa Therapeutics stock price today?▼
The current price of ATOS is $2.57 USD — it has decreased by -7.89% in the past 24 hours. Watch Atossa Therapeutics stock price performance more closely on the chart.
What is Atossa Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Atossa Therapeutics stocks are traded under the ticker ATOS.
Is Atossa Therapeutics stock price growing?▼
ATOS stock has risen by +8.89% compared to the previous week, the month change is a +3.2% rise, over the last year Atossa Therapeutics has showed a -78.31% decrease.
What is Atossa Therapeutics market cap?▼
Today Atossa Therapeutics has the market capitalization of 25.65M
When is the next Atossa Therapeutics earnings date?▼
Atossa Therapeutics is going to release the next earnings report on November 16, 2026.
What were Atossa Therapeutics earnings last quarter?▼
ATOS earnings for the last quarter are -0.95 USD per share, whereas the estimation was -1.03 USD resulting in a +7.32% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Atossa Therapeutics revenue for the last year?▼
Atossa Therapeutics revenue for the last year amounts to 0 USD.
What is Atossa Therapeutics net income for the last year?▼
ATOS net income for the last year is -34.77M USD.
How many employees does Atossa Therapeutics have?▼
As of August 18, 2026, the company has 14 employees.
In which sector is Atossa Therapeutics located?▼
Atossa Therapeutics operates in the Health & Wellness sector.
When did Atossa Therapeutics complete a stock split?▼
The last stock split for Atossa Therapeutics was on February 02, 2026 with a ratio of 1:15.
Where is Atossa Therapeutics headquartered?▼
Atossa Therapeutics is headquartered in SEATTLE, United States.